

が唯一独立因子として抽出された。

#### D. 考察

C型慢性肝炎に対するIFN治療でSVRが得られると肝癌の発生が抑えられることはすでによく知られている。また、IFNを投与することによりALT、AFPの有意な低下を認める。

一方、C型肝硬変患者においてIFN治療後の発癌は、どのような患者群においてみられるかはまだ不明な点も多い。IFN治療群は、未治療群と比べ発癌のリスクを12.8%減少させた報告やSVRが得られた場合は発癌リスクを19.1%抑制するとも言われている。

今回の検討において、SVRが得られた症例は、有意に発癌のリスクを低下させた。さらに、多変量解析の結果、治療終了時のAFP値が肝発癌と関係する独立した因子となり、AFPが10 ng/ml未満の場合、累積発癌率を有意に低下させた。これらのことから、IFN治療でSVRが得られなくてもAFP値を10 ng/ml未満にすることにより肝発癌のリスクを低下させることができると考えられた。

#### E. 結論

C型肝硬変患者のIFN治療において、AFP値が10 mg/ml未満であれば有意に肝発癌を低下させた。したがって、IFN治療終了時にAFP10 ng/ml未満は、肝発癌の低リスク患者群を予測する最も有用な因子になると考えられた。

#### F. 健康危険情報

特記すべきことなし。

#### G. 研究発表

##### 1. 論文発表

- 1) Ide T, Sata M, Sakisaka S, Nakamuta M, Fujiyama S, Mizuta T, Tahara K, Fujisaki K, Komorizono Y, Watanabe H, Morita Y, Tsubouchi H. Peginterferon-alpha-2b plus ribavirin therapy in patients with chronic

hepatitis C as assessed by a multi-institutional questionnaire in Japan. *Hepatology Res* 2010; 40 (6): 557-565.

##### 2. 学会発表

- 1) 坂本雅晴、釈迦堂敏、森原大輔、西澤新也、櫻井邦俊、上田秀一、岩下英之、横山圭二、阿南 章、竹山康章、入江 真、岩田 郁、早田哲郎、向坂彰太郎. C型肝硬変に対するインターフェロン治療後の発癌抑制とAFP値の関連. 第46回日本肝臓学会総会、山形、平成22年5月
- 2) 森原大輔、釈迦堂敏、西澤新也、西中村瞳、岩下英之、櫻井邦俊、上田秀一、横山圭二、坂本雅晴、阿南 章、竹山康章、入江 真、岩田 郁、早田哲郎、向坂彰太郎. C型慢性肝炎に対するペグインターフェロン+リバビリン併用療法における *Helicobacter pylori* 感染の影響. 第46回日本肝臓学会総会、山形、平成22年5月
- 3) 釈迦堂敏、入江 真、櫻井邦俊、上田秀一、岩下英之、森原大輔、横山圭二、西澤新也、阿南 章、竹山康章、坂本雅晴、岩田 郁、早田哲郎、向坂彰太郎. B型慢性肝炎に対するエンテカビル治療の現状とエンテカビル耐性ウイルス出現因子の検討. 第46回日本肝臓学会総会、山形、平成22年5月
- 4) 西澤新也、釈迦堂敏、森原大輔、西中村瞳、櫻井邦俊、岩下英之、上田秀一、横山圭二、坂本雅晴、阿南 章、竹山康章、入江 真、岩田 郁、早田哲郎、向坂彰太郎. HCVがHBVの感染状態に与える影響. 第46回日本肝臓学会総会、山形、平成22年5月

#### H. 知的所有権の出願・取得状況

##### 1. 特許取得

今回の研究内容については特になし。

##### 2. 実用新案登録

特記すべきことなし。

##### 3. その他

特記すべきことなし

## IV. 研究成果の刊行物・別刷

IV. 研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
芥田憲夫 熊田博光	肝疾患治療薬～B型・C型肝炎における抗ウイルス療法・抗炎症療法～	高久史麿	治療薬ハトブック2010	じほう	東京都	2010	513-533
熊田博光	C型肝炎の診療ガイドライン	幕内雅敏 菅野健太郎 工藤正俊	今日の消化器疾患治療指針 第3版	Medic Media	東京都	2010	991-993
岡上 武	慢性肝炎の治療(B型)	幕内雅俊、 菅野健太郎、 工藤正俊。	今日の消化器疾患治療指針	医学書院	東京	2010	580-583
黒崎雅之、 泉並木	B型肝炎に対する抗ウイルス治療	林紀夫、 日比紀文、 上日紀夫	Annual Review 消化器	中外医学社	東京	2011	137-45
田中智大、 泉並木	肝臓癌	佐藤千史、 井上智子	人体の構造と機能からみた病態生理	金原出版	東京	2010	93-100
工藤正俊、 泉並木	序文	工藤正俊、 泉並木	ウイルス肝炎の治療戦略	診断と治療社	東京	2010	vi-vii
田中榮司、 宮川眞一、 角谷眞澄		田中榮司、 宮川眞一、 角谷眞澄	肝疾患クリニカルスタンダード	文光堂	東京	2010	
清家正隆	NASH	犀川哲展 吉松博信	糖尿病と心臓病	医学書院	東京	2010	34-41
清家正隆	脂肪肝	吉松博信	肥満症	日本医事新報社	東京	2010	69-74

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Suzuki F, Suzuki Y, Akuta N, Sezaki H, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Chayama K, Kamatani N, Miyakawa Y, <u>Kumada H</u>	Influence of ITPA Polymorphisms on Decrease of hemoglobin during treatment with pegylated interferon, ribavirin and telaprevir	Hepatology	53 (2)	416-421	2011
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Kumada H</u> .	Amino acid substitutions in HCV core region and genetic variation near the interleukin 28B gene effect viral dynamics during telaprevir with peginterferon and ribavirin	Intervirology	DOI: 10.1159/000323526	In press	2011
Tadokoro K, Suzuki F, Kobayashi M, Yamaguchi T, Nagano M, Egashira T, <u>Kumada H</u>	Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-invader assay.	J Virol Method	171	67-73	2011
Hayes CN, Kobayashi M, Akuta N, Suzuki F, <u>Kumada H</u> , Abe H, Miki D, Imamura M, Ochi H, Kamatani N, Nakamura Y, Chayama K.	HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.	Gut.	60	261-267	2011
Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, Tanaka E, <u>Kumada H</u> , Izumi N, Mizokami M, Kudo M.	Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009.	Hepatol Res.	41	1-21	2011
Chayama K, Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, zumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, <u>Kumada H</u> .	Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C.	Hepatol Res.	in press	in press	2011
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Kumada H</u> .	Amino acid substitutions in the hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to Telaprevir with peginterferon and ribavirin	Hepatology	52 (2)	421-429	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kobayashi M, Akuta N, Suzuki F, Hosaka T, Sezaki H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Mineta R, Iwasaki S, Miyakawa Y, <u>Kumada H.</u>	Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b.	J Med Virol	82	41-48	2010
Suzuki F, Suzuki Y, Akuta N, Sezaki H, Yatsuji H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Iwasaki S, <u>Kumada H.</u>	Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.	J cln virol	47 (1)	76-78	2010
Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Sezaki H, Hosaka T, Kawamura Y, Yatsuji H, Hirakawa M, Ikeda K, Kobayashi M, <u>Kumada H.</u>	Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus.	J Med Virol	82	390-395	2010
Kobayashi M, Suzuki F, Akuta N, Yatsuji H, Hosaka T, Sezaki H, Kobayashi M, Kobayashi M, Kawamura Y, Suzuki Y, Arase Y, Ikeda K, Mineta R, Iwasaki S, Watahiki S, <u>Kumada H.</u>	Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment.	Hepatol Res	40 (2)	125-134	2010
Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, <u>Kumada H.</u>	Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants.	Hepatol Res	40 (2)	145-152	2010
<u>Kumada H.</u> , Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, Cyayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y.	Guidelines for the treatment of chronic hepatitis and cirrhosis induced by hepatitis B virus infection for the fiscal year 2008 in Japan.	Hepatol Res	40 (1)	1-7	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Kumada H</u> , Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, Cyayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y.	Guidelines for the treatment of cronic hepatitis and cirrhosis induced by hepatitis C virus infection for the fiscal year 2008 in Japan.	Hepatol Res	40 (1)	8-13	2010
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suziki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Kumada H</u> .	Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.	J Med Virol	82	575-582	2010
Watanabe S, Enomoto N, Koike K, Isumi N, Takikawa H, Hashimoto E, Moriyasu F, <u>Kumada H</u> , Imawari M, PERFECT study group.	Prolonged treatment with pegylated interferon $\alpha$ 2b plus ribavirin improves sustaind virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan.	Hepatol Res	40	135-144	2010
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suziki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Kumada H</u>	Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases.	Intervirol	53	188-192	2010
Arase Y, Suzuki F, Akuta N, Sezaki H, Suziki Y, Kawamura Y, Kobayashi M, Hosaka T, Yatsuji H, Hirakawa M, Saitoh S, Ikeda K, Kobayashi M, <u>Kumada H</u> .	Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load.	Int Med	49	957-963	2010
Suzuki F, Akuta N, Suziki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, <u>Kumada H</u> .	Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients.	Hepatol Res	25	892-898	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, <u>Kumada H.</u>	HBcrAg is predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.	Liv Int	93 (3-4)	109-112	2010
Kawamura Y, Ikeda K, Hirakawa M, Yatsuji H, Hosaka T, Sezaki H, Kobayashi M, Kobayashi M, Suzuki Y, Arase Y, <u>Kumada H.</u>	New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma.	Hepatol Res	40 (10)	1006-1014	2010
Ikeda K, Kobayashi M, Seko Y, Imai N, Hirakawa M, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, <u>Kumada H.</u>	Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer.	Hepatol Res	40 (12)	1168-1175	2010
Kawamura Y, Ikeda K, Hirakawa M, Yatsuji H, Hosaka T, Sezaki H, Kobayashi M, Kobayashi M, Suzuki Y, Arase Y, <u>Kumada H.</u>	Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients.	Am J Med	123 (10)	951-956	2010
Hashimoto Y, Suzuki F, Hirakawa M, Kawamura Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki Y, Kobayashi M, Arase Y, Ikeda K, <u>Kumada H.</u>	Clinical and virological effects of long-term (over 5 years) lamivudine therapy.	J Med Virol	82	684-691	2010
Suzuki Y, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Miyakawa Y, <u>Kumada H.</u>	Association of HLA-DR14 with Treatment Response in Japanese Patients with Autoimmune Hepatitis.	Dig Dis Sci	55	2070-2076	2010
Izumi N, Nishiguchi S, Hino K, Suzuki F, <u>Kumada H.</u> Itoh Y, Asahina Y, Tamori A, Hiramatsu N, Hayashi N, Kudo M	Management of hepatitis C: report of the consensus meeting at the 45 <sup>th</sup> annual meeting of the Japan Society of Hepatology (2009).	Hepatol Res	40	347-68	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
瀬崎ひとみ、鈴木文孝、芥田憲夫、平川美晴、川村祐介、八辻寛美、保坂哲也、小林正宏、鈴木義之、斎藤聡、荒瀬康司、池田健次、熊田博光	C型慢性肝炎に対するペグインターフェロンとリバビリン併用療法におけるNS3-4Aプロテアーゼ阻害剤(Telaprevir)併用12週間治療のウイルス学的効果の検討	肝臓	51 (7)	394-396	2010
八辻寛美、鈴木文孝、平川美晴、川村祐介、瀬崎ひとみ、保坂哲也、芥田憲夫、小林正宏、鈴木義之、斎藤聡、荒瀬康司、池田健次、岩崎里美、峰田理恵、綿引祥予、小林万利子、熊田博光	核酸アナログ未使用のB型慢性肝炎症例へのエンテカビル治療中に r t A181Tウイルスが増殖した一症例	肝臓	51 (4)	196-198	2010
小林万利子、鈴木文孝、芥田憲夫、鈴木義之、瀬崎ひとみ、八辻寛美、保坂哲也、小林正宏、川村祐介、平川美晴、荒瀬康司、池田健次、峰田理恵、岩崎里美、綿引祥予、中村祐輔、茶山一彰、熊田博光	IL28BとHCV Core aa70置換との関連	肝臓	51 (6)	322-323	2010
Yasui K, Harano Y, Mitsuyoshi H, Tsuji K, Endo M, Nakajima T, Minami M, Itoh Y, Zen Y, Nakanuma Y, Yoshikawa T, <u>Okanoue T.</u>	Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus.	J Gastroenterol	45	95-104	2010
Tsuji K, Yasui K, Gen Y, Endo M, Dohi O, Zen K, Mitsuyoshi H, Minami M, Itoh Y, Taniwaki M, Tanaka S, Arie S, <u>Okanoue T.</u> , Yoshikawa T.	PEG10 is probable target for the amplification at 7q21 detected in hepatocellular carcinoma.	Cancer Genetics Cytogenetics	198	118-125	2010
Fujii H, Itoh Y, Sakamoto M, Ohkawara T, Sawa Y, Nishida K, Nishimura T, Yamaguchi K, Yasui K, Minami M, <u>Okanoue T.</u> , Yoshikawa T.	Relapse of hepatitis C in a pegylated-interferon- $\alpha$ 2b plus ribavirin-treated sustained virological responder.	Hepatol Res	30	654-660	2010
小関至、木村睦海、荒川智宏、中島知明、桑田靖昭、赤池淳、木村卓味、佐藤隆啓、狩野吉康、豊田成司	ラミブジンとアデフォビル併用不応例に対するアデフォビルとエンテカビル併用療法	日消誌	108	202-209	2011



発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Koizumi Y, Hirooka M, Kisaka Y, Konishi I, Abe M, Murakami H, Matsuura B, Hiasa Y, <u>Onji M</u>	Liver fibrosis in patients with chronic hepatitis C noninvasive diagnosis of by means of real-time tissue elastography:Establishment of the method for measurement.	Radiology	258	610-617	2011
Ueda T, Matsuura B, Miyake T, Furukawa S, Abe M, Hiasa Y, <u>Onji M</u>	Mutational analysis of predicted extracellular domains of human growth hormone secretagogue receptor 1a.	Regul Pept	166	28-35	2011
Akbar SMF, Horiike N, Chen S, Michitaka K, Abe M, Hiasa Y, Matsuura B, <u>Onji M</u>	Mechanism of restoration of immune responses of patients with chronic hepatitis B patients during lamivudine therapy:increased antigen processing and presentation by dendritic cells.	J Viral Hepatitis	18 (3)	200-205	2011
Miyake T, Akbar SMF, Yoshida O, Chen S, Hiasa Y, Matsuura B, Abe M, <u>Onji M</u>	Impaired dendritic cell functions disrupt antigen-specific adaptive immune responses in mice with nonalcoholic fatty liver disease.	J Gastrol	45	859-867	2010
Kisaka Y, Hirooka M, Koizumi Y, Abe M, Matsuura B, Hiasa Y, <u>Onji M</u>	Contrast-enhanced sonography with abdominal virtual sonography in monitoring radiofrequency ablation of hepatocellular carcinoma.	J clin ultrasound	38 (3)	138-144	2010
Hirooka M, Koizumi Y, Kisaka Y, Abe M, Murakami H, Matsuura B, Hiasa Y, <u>Onji M</u>	Mass reduction by radiofrequency ablation before hepatic arterial infusion chemotherapy improved prognosis for patients with huge hepatocellular carcinoma and portal vein thrombus.	AJR Am J Roentgenol	194 (2)	W221-226	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Akbar SMF, Yoshida O, Chen S, Aguilar JC, Abe M, Matsuura B, Hiasa Y, <u>Onji M</u>	Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection.	Antiviral Therapy	15 (6)	887-895	2010
Hiraoka A, Kojiro M, Horiike N, Hidaka S, Uehara T, Ichikawa S, Hasebe A, Miyamoto Y, Ninomiya T, Sogabe I, Ishimaru Y, Kawasaki H, Koizumi Y, Hirooka M, Yamashita Y, Abe M, Hiasa Y, Matsuura B, <u>Onji M</u>	Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients.	J Gastroenterol Hepatol	25 (2)	403-407	2010
Tamura Y, Igarashi M, Suda T, Wakai T, Shirai Y, Umemura T, Tanaka E, Kakizaki S, Takagi H, Hiasa Y, <u>Onji M</u> , Aoyagi Y	Fucosylated Fraction of Alpha-Fetoprotein as a Predictor of Prognosis in Patients with Hepatocellular Carcinoma After Curative Treatment.	Dig Dis Sci	55	2095-2101	2010
Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, <u>Onji M</u>	Etiology of liver cirrhosis in Japan: a nationwide survey.	Journal of Gastroenterology	45 (1)	86-94	2010
<u>Moriwaki H</u> , Shiraki M, Iwasa J, Terakura Y.	Hepatic encephalopathy as a complication of liver cirrhosis: an Asian perspective.	J Gastroenterol Hepatol	25	858-863	2010
Ito H, Hoshi M, Ohtaki H, Taguchi A, Ando K, Ishikawa T, Osawa Y, Hara A, <u>Moriwaki H</u> , Saito K, Seishima M.	Ability of IDO to attenuate liver injury in alpha-galactosylceramide-induced hepatitis model.	J Immunol	185	4554-4560	2010
Osawa Y, Seki E, Adachi M, Suetsugu A, Ito H, <u>Moriwaki H</u> , Seishima M, Nagaki M.	Role of acid sphingomyelinase of Kupffer cells in cholestatic liver injury in mice.	Hepatology	51	237-245	2010
Shiraki M, Terakura Y, Iwasa J, Shimizu M, Miwa Y, Murakami N, Nagaki M, <u>Moriwaki H</u> .	Elevated serum tumor necrosis factor-alpha and soluble tumor necrosis factor receptors correlate with aberrant energy metabolism in liver cirrhosis.	Nutrition	26	269-275	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Iwasa J, Shimizu M, Shiraki M, Shirakami Y, Sakai H, Terakura Y, Takai K, Tsurumi H, Tanaka T, <u>Moriwaki H.</u>	Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ- <i>db/db</i> mice.	Cancer Sci	101	460-467	2010
Kumada H, Okanoue T, Onji M, <u>Moriwaki H.</u> Izumi N, Tanaka E, Chayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y; The Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis, Ministry of Health, Labor and Welfare of Japan.	Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan.	Hepatol Res	40	1-7	2010
Kumada H, Okanoue T, Onji M, <u>Moriwaki H.</u> Izumi N, Tanaka E, Chayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y; The Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis, Ministry of Health, Labour and Welfare of Japan.	Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan.	Hepatol Res	40	8-13	2010
Imai K, Takai K, Nishigaki Y, Shimizu S, Naiki T, Hayashi H, Uematsu T, Sugihara J, Tomita E, Shimizu M, Nagaki M, <u>Moriwaki H.</u>	Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in HCV-positive patients: A prospective, case-series study.	Hepatol Res	40	376-382	2010
Komi Y, Sogabe Y, Ishibashi N, Sato Y, <u>Moriwaki H.</u> Shimokado K, Kojima S.	Acyclic retinoid inhibits angiogenesis by suppressing the MAPK pathway.	Lab Invest	90	52-60	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Izumi N</u> , Asahina Y, Kurosaki M.	Predictions of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors.	Hepat Res Treat	In press		2011
<u>Izumi N</u> .	Recent advances of radiofrequency ablation for early hepatocellular carcinoma.	J Gastroenterol Hepatol	26S	115-22	2011
Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, Yasui Y, Hosokawa T, Ueda, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, <u>Izumi N</u> .	Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection.	Hepatology	52	518-27	2010
Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, <u>Izumi N</u> , Mizokami M.	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.	J Hepatol	In press		2010
Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Tamori A, Nakagawa M, <u>Izumi N</u> .	Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: Dta maining analysis.	J Med Virol	In press		2010
<u>Izumi N</u> .	Diagnosis and treatment algorithm of the Japanese society of Hepatology: a consensus-based practice guideline.	Oncology	78	78-86	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kurosaki M, Hosokawa T, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, <u>Izumi N</u> .	Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy.	Hepatol Res	40	870-877	2010
Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, Tanaka E, Kumada H, <u>Izumi N</u> , Mizokami M, Kudo M.	Management of hepatitis B: consensus of the Japan Society of Hepatology 2009.	Hepatol Res	41	1-21	2011
Chayama K, Hayes CN, Yoshida K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, <u>Izumi N</u> , Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H.	Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C.	Hepatol Res	40	1155-1167	2010
Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Yatsushashi H, <u>Izumi N</u> .	Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.	J Gastroenterol	In press		2010
Karino Y, Toyota J, Kumada H, Katano Y, <u>Izumi N</u> , Kobashi H, Sata M, Moriyama M, Imazeki F, Kage M, Ishikawa H, Masaki N, Seriu T, Omata M.	Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B.	Hepatol Int	4	414-422	2010
<u>Izumi N</u> , Nishiguchi S, Hino K, Suzuki F, Kumada H, Itoh Y, Asahina Y, Tamori A, Hiramatsu N, Hayashi N, Kudo M.	Management of hepatitis C; report of the consensus meeting at the 45 <sup>th</sup> annual meeting of the Japan Society of Hepatology (2009).	Hepatol Res	40	347-68	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kumada H, Okanoue T, Onji M, Moriwaki H, <u>Izumi N</u> , Tanaka E, Chayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y	The study group for the standardization of treatment of viral hepatitis including cirrhosis, ministry of health, labor and welfare of Japan. Guidelines for the treatment of chronic hepatitis due to hepatitis C virus infection for the fiscal year 2008 in Japan.	Hepatol Res.	40	1-7	2010
Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Tuchiya K, Nakanishi H, Ikeda H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, <u>Izumi N</u> .	A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis.	Hepatol Res	40	251-60	2010
Watanabe S, Enomoto N, Koike K, <u>Izumi N</u> , Takikawa H, Hashimoto E, Moriyasu F, Kumada H, Imawari M; PERFECT study group.	Prolonged treatment with pegylated interferon alpha2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan.	Hepatol Res	40	135-44	2010
Itakura J, Kurosaki M, Itakura Y, Maekawa S, Asahina Y, <u>Izumi N</u> , Enomoto N.	Reproducibility and usability of chronic virus infection model using agent-based simulation; comparing with a mathematical model.	Biosystems	99	70-8	2010
Yoneda S, Umemura T, Katsuyama Y, Kamijo A, Joshita S, Komatsu M, Ichijo T, Matsumoto A, Yoshizawa K, Ota M, <u>Tanaka E</u>	Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients.	J Infect Dis			In press
Umemura T, Zen Y, Hamano H, Joshita S, Ichijo T, Yoshizawa K, Kiyosawa K, Ota M, Kawa S, Nakanuma Y, <u>Tanaka E</u> .	Clinical significance of immunoglobulin G4-associated autoimmune hepatitis.	J Gastroenterol	46 (suppl)	48-55	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, <u>Tanaka E</u> , Kumada H, Izumi N, Mizokami M, Kudo M.	Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009.	Hepatol Res	41 (1)	1-21	2011
Hatta T, Fujinaga Y, Kadoya M, Ueda H, Murayama H, Kurozumi M, Ueda K, Komatsu M, Nagaya T, Joshita S, Kodama R, <u>Tanaka E</u> , Uehara T, Sano K, Tanaka N.	Accurate and simple method for quantification of hepatic fat content using magnetic resonance imaging: a prospective study in biopsy-proven nonalcoholic fatty liver disease.	J Gastroenterol	45 (12)	1263-71	2010
Joshita S, Nakazawa K, Koike S, Kamijo A, Matsubayashi K, Miyabayashi H, Furuta K, Kitano K, Yoshizawa K, <u>Tanaka E</u> .	A case of granulocyte-colony stimulating factor-producing hepatocellular carcinoma confirmed by immunohistochemistry.	J Korean Med Sci	25 (3)	476-80	2010
Joshita S, Umemura T, Yoshizawa K, Katsuyama Y, <u>Tanaka E</u> , Nakamura M, Ishibashi H, Ota M.	Association analysis of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with primary biliary cirrhosis in Japanese patients.	J Hepatol	53 (3)	537-41	2010
Joshita S, Umemura T, Yoshizawa K, Katsuyama Y, <u>Tanaka E</u> , Ota M.	A2BP1 as a novel susceptible gene for primary biliary cirrhosis in Japanese patients.	Hum Immunol	71 (5)	520-4	2010
Joshita S, Yoshizawa K, Sano K, Kobayashi S, Sekiguchi T, Morita S, Kamijo A, Komatsu M, Umemura T, Ichijo T, Matsumoto A, <u>Tanaka E</u> .	A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome.	Intern Med	49 (11)	991-4	2010
Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, <u>Tanaka E</u> , Chayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y.	Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan.	Hepatol Res	40 (1)	1-7	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, <u>Tanaka E</u> , Chayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y.	Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan.	Hepatol Res	40 (1)	8-13	2010
Matsumoto A, Maki N, Yoshizawa K, Umemura T, Joshita S, <u>Tanaka E</u> .	Comparison of hepatitis B virus DNA, RNA, and core related antigen as predictors of lamivudine resistance in patients with chronic hepatitis B	Shinshu Medical Journal	58 (4)	153-62	2010
Nagaya T, Tanaka N, Suzuki T, Sano K, Horiuchi A, Komatsu M, Nakajima T, Nishizawa T, Joshita S, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Nakayama J, <u>Tanaka E</u> , Aoyama T.	Down-regulation of SREBP-1c is associated with the development of burned-out NASH.	J Hepatol	53 (4)	724-31	2010
Tamura Y, Igarashi M, Suda T, Wakai T, Shirai Y, Umemura T, <u>Tanaka E</u> , Kakizaki S, Takagi H, Hiasa Y, Onji M, Aoyagi Y.	Fucosylated fraction of alpha-fetoprotein as a predictor of prognosis in patients with hepatocellular carcinoma after curative treatment.	Dig Dis Sci	55 (7)	2095-101	2010
Tanaka N, Zhang X, Sugiyama E, Kono H, Horiuchi A, Nakajima T, Kanbe H, <u>Tanaka E</u> , Gonzalez FJ, Aoyama T.	Eicosapentaenoic acid improves hepatic steatosis independent of PPARalpha activation through inhibition of SREBP-1 maturation in mice.	Biochem Pharmacol	80 (10)	1601-12	2010
Tsuruta G, Tanaka N, Hongo M, Komatsu M, Horiuchi A, Hamamoto K, Iguchi C, Nakayama Y, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Aoyama T, <u>Tanaka E</u> .	Nonalcoholic fatty liver disease in Japanese junior high school students: its prevalence and relationship to lifestyle habits.	J Gastroenterol	45 (6)	666-72	2010



発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tsutsui M, Tanaka N, Kawakubo M, Sheena Y, Horiuchi A, Komatsu M, Nagaya T, Joshita S, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Aoyama T, <u>Tanaka E</u> , Sano K.	Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels.	J Clin Gastroenterol	44 (6)	440-7	2010
Uehara T, Hamano H, Kawa S, Sano K, Oki K, Kobayashi Y, Nagaya T, Akamatsu T, Kurozumi M, Fujinaga Y, <u>Tanaka E</u> , Honda T, Ota H.	Chronic gastritis in the setting of autoimmune pancreatitis.	Am J Surg Pathol	34 (9)	1241-9	2010
田中榮司	B型肝炎再活性化の病態と対策	日本消化器病学会雑誌	107 (9)	1417-25	2010
溝上雅史, 田中榮司, 茶山一彰, 田中靖人, 黒崎雅之, 泉並木, 荒瀬康司, 熊田博光, 今関文夫, 横須賀収, 工藤正俊.	日本肝臓学会コンセンサス神戸2009 B型肝炎の診断と治療	肝臓	51 (5)	243-60	2010
Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, Tsunoda T, Hayes CN, Kumada H, Nakamura Y, <u>Chayama K</u> .	ITPA Polymorphism Affects Ribavirin-induced Anemia and Outcome of Therapy - a Genome-wide Study of Japanese HCV Patients.	Gastroenterology.	139 (4)	1190-7	2010
Kamiya N, Iwao E, Hiraga N, Tsuge M, Imamura M, Takahashi S, Miyoshi S, Tatenno C, Yoshizato K, <u>Chayama K</u> .	Practical Evaluation of a Mouse with Chimeric Human Liver Model for Hepatitis C Virus Infection Using an NS3-4A Protease Inhibitor.	J Gen Virol	91 (Pt 7)	1668-77	2010
Tsuge M, Hiraga N, Akiyama R, Tanaka S, Matsushita M, Mitsui F, Abe H, Kitamura S, Hatakeyama T, Kimura T, Miki D, Mori N, Imamura M, Takahashi S, Hayes CN, <u>Chayama K</u> .	HBx protein is indispensable for development of viremia in human hepatocyte chimeric mice.	J Gen Virol	91 (Pt 7)	1854-64	2010
Huang YW, <u>Chayama K</u> , Tsuge M, Takahashi S, Hatakeyama T, Abe H, Hu JT, Liu CJ, Lai MY, Chen DS, Yang SS, Kao JH.	Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B.	AntivirTher	15 (2)	177-84	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yokosuka O, Takaguchi K, Fujioka S, Shindo M, <u>Chayama K</u> , Kobashi H, Hayashi N, Sato C, Kiyosawa K, Tanikawa K, Ishikawa H, Masaki N, Seriu T, Omata M.	Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection.	J Hepatol	52 (6)	791-9	2010
Mitsui F, Tsuge M, Kimura T, Kitamura S, Abe H, Saneto H, Kawaoka T, Miki D, Hatakeyama T, Hiraga N, Imamura M, Kawakami Y, Aikata H, Takahashi S, Hayes CN, Igarashi H, Morimoto K, Shimizu M, <u>Chayama K</u> .	Importance of serum concentration of adefovir for Lamivudine-adefovur combination therapy in patients with lamivudine-resistant chronic hepatitis B.	Antimicrob Agents Chemother	54 (8)	3205-11	2010
Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, Miki D, Mitsui F, Hiraga N, Imamura M, Takahashi S, Ohishi W, Arihiro K, Kubo M, Nakamura Y, <u>Chayama K</u> .	Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.	J Hepatol.	53 (3)	439-43	2010
Mishima K, Sakamoto N, Sekine-Osajima Y, Nakagawa M, Itsui Y, Azuma S, Kakinuma S, Kiyohashi K, Kitazume A, Tsuchiya K, Imamura M, Hiraga N, <u>Chayama K</u> , Wakita T, Watanabe M.	Cell culture and in vivo analyses of cytopathic hepatitis C virus mutants.	Virology.	405 (2)	361-9	2010
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Chayama K</u> , Nakamura Y, Kumada H.	Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.	Hepatology	52 (2)	421-9	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kawaoka T, Hiraga N, Takahashi S, Takaki S, Mitsui F, Tsuge M, Nagaoki Y, Kimura Y, Hashimoto Y, Katamura Y, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Aikata H, Tashiro H, Ohdan H, <u>Chayama K</u> .	Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus.	Scand J Gastroenterol	45 (12)	1488-1496	2010
Suda G, Sakamoto N, Itsui Y, Nakagawa M, Tasaka-Fujita M, Funaoka Y, Watanabe T, Nitta S, Kiyohashi K, Azuma S, Kakinuma S, Tsuchiya K, Imamura M, Hiraga N, <u>Chayama K</u> , Watanabe M.	IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones.	Virology	10407 (1)	80-90	2010
<u>Chayama K</u> , Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H.	Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C.	Hepatol Res	in press	in press	2011
Ide T, Sata M, <u>Chayama K</u> , Shindo M, Toyota J, Mochida S, Tomita E, Kumada H, Yamada G, Yatsushashi H, Hayashi N, Ishikawa H, Seriu T, Omata M.	Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy.	Hepatol Int	8:4 (3)	594-600	2010
Chayama K, Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, <u>Sakisaka S</u> , Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H.	Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C.	Hepatol Res	Epub ahead of print	Epub ahead of print	2010 Oct 7
Ide T, Sata M, <u>Sakisaka S</u> , Nakamuta M, Fujiyama S, Mizuta T, Tahara K, Fujisaki K, Komorizono Y, Watanabe H, Morita Y, Tsubouchi H	Peginterferon-alpha-2b plus ribavirin therapy in patients with chronic hepatitis C as assessed by a multi-institutional questionnaire in Japan	Hepatol Res	40	557-565	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Miyagi T, <u>Takehara T</u> , Nishio K, Shimizu S, Kohga K, Tatsumi T, Kanto T, Hiramatsu N, Hayashi N.	Altered interferon-alpha-signaling in NK cells from the patients with chronic hepatitis C virus infection.	J Hepatol	53	424-430	2010
Nishida C, Uto H, <u>Oketani M</u> , Tokunaga K, Nosaki T, Fukumoto M, Oku M, Sogabe A, Moriuchi A, Ido A, Tsubouchi H.	Clinical significance of alanine aminotransferase levels and the effect of ursodeoxycholic acid in hemodialysis patients with chronic hepatitis C.	J Gastroenterol	45 (3)	326-34	2010
桶谷 眞、坪内博仁.	B型肝炎再活性化による劇 症肝炎の現状と対策	日本消化器病 学会雑誌	107 (9)	1426-1433	2010
山田典栄、 <u>四柳宏</u> 、奥瀬千晃、 安田清美、鈴木道博、小池和彦	B型急性肝炎におけるHBs 抗原陽性持続期間の検討	肝臓	51 (9)	534-535	2010
Kainuma M, Furusyo N, Kajiwara E, Takahashi K, <u>Nomura H</u> , Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Shimono J, Shimoda S, Hayashi J	Pegylated interferon $\alpha$ -2b plus ribavirin for older patients with chronic hepatitis C.	World J Gastroenterol.	16	4400-4409	2010
Nishimura J, Masaki T, Arakawa M, <u>Seike M</u> , Yoshimatsu H.	Isoleucine prevents the accumulation of tissue triglycerides and upregulates the expression of PPARalpha and uncoupling protein in diet-induced obese mice.	J Nutr.	140	496-500	2010
Arakawa M, Masaki T, Nishimura J, <u>Seike M</u> , Yoshimatsu H.	The effects of branched-chain amino acid granules on the accumulation of tissue triglycerides and uncoupling proteins in diet-induced obese mice.	Endocr J	58 (3)	161-170	2011
Kondo Y, <u>Ueno Y</u> , Kakazu E, Kobayashi K, Shiina M, Tamai K, Machida K, Inoue J, Wakui Y, Fukushima K, Obara N, Kimura O, Shimosegawa T.	Lymphotropic HCV strain can infect human primary naive CD4(+) cells and affect their proliferation and IFN-gamma secretion activity.	J Gastroenterol	46	232-41	2011